PD-L1 binding polypeptide or composite
AssigneeSuzhou Alphamab Co., Ltd.
InventorsTing Xu, Aiwu Zhou, Yuhao Jin, Ling Wang, Jie Wu, Hongqin Hu, Xiaoxiao Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.
Claims11
An isolated polypeptide comprising an amino acid sequence set forth in SEQ ID NO:
- 4, which is capable of specifically binding to human PD-L1 and blocking the interaction of PD-L1 and PD1,
- wherein the polypeptide does not comprise the amino acid sequence of SEQ ID NO:
- 2 and/or SEQ ID NO:
- 3, and
- wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:
- 10, 12, 16-18, 20, and/or 23.
A method of producing a polypeptide that binds to PD-L1 and an additional target, comprising replacing the CDR1 and/or the CDR2 of the antibody of SEQ ID NO:
- 1 with CDR(s) of an antibody that recognizes the additional target and/or a polypeptide that binds to the additional target, thereby producing a polypeptide that binds to PD-L1 and the additional target.
A method of producing a polypeptide that binds to PD-L1 and an additional target, comprising grafting the CDR3 of the antibody of SEQ ID NO:
- 1 onto an antibody recognizing the additional target, thereby producing a polypeptide that binds to PD-L1 and the additional target.
A method of producing a PD-L1 binding non-immunoglobulin, comprising grafting the CDR3 of the antibody of SEQ ID NO:
- 1 onto a non-immunoglobulin having a CDR loop-like structure, thereby allowing the non-immunoglobulin to bind to PD-L1.
Dependencies are inferred from the claim text.